1
|
Penco-Campillo M, Molina C, Piris P, Soufi N, Carré M, Pagnuzzi-Boncompagni M, Picco V, Dufies M, Ronco C, Benhida R, Martial S, Pagès G. Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas. Cells 2022; 11:cells11233933. [PMID: 36497191 PMCID: PMC9738107 DOI: 10.3390/cells11233933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 11/28/2022] [Accepted: 11/30/2022] [Indexed: 12/12/2022] Open
Abstract
Medulloblastoma (MB) is the most common and aggressive paediatric brain tumour. Although the cure rate can be as high as 70%, current treatments (surgery, radio- and chemotherapy) excessively affect the patients' quality of life. Relapses cannot be controlled by conventional or targeted treatments and are usually fatal. The strong heterogeneity of the disease (four subgroups and several subtypes) is related to innate or acquired resistance to reference treatments. Therefore, more efficient and less-toxic therapies are needed. Here, we demonstrated the efficacy of a novel inhibitor (C29) of CXCR1/2 receptors for ELR+CXCL cytokines for the treatment of childhood MB. The correlation between ELR+CXCL/CXCR1/2 expression and patient survival was determined using the R2: Genomics Analysis and Visualization platform. In vitro efficacy of C29 was evaluated by its ability to inhibit proliferation, migration, invasion, and pseudo-vessel formation of MB cell lines sensitive or resistant to radiotherapy. The growth of experimental MB obtained by MB spheroids on organotypic mouse cerebellar slices was also assayed. ELR+CXCL/CXCR1/2 levels correlated with shorter survival. C29 inhibited proliferation, clone formation, CXCL8/CXCR1/2-dependent migration, invasion, and pseudo-vessel formation by sensitive and radioresistant MB cells. C29 reduced experimental growth of MB in the ex vivo organotypic mouse model and crossed the blood-brain barrier. Targeting CXCR1/2 represents a promising therapeutic strategy for the treatment of paediatric MB in first-line treatment or after relapse following conventional therapy.
Collapse
Affiliation(s)
- Manon Penco-Campillo
- Institute for Research on Cancer and Aging (IRCAN), Université Côte d’Azur, CNRS UMR 7284 and INSERM U1081, 33 Avenue de Valombrose, 06107 Nice, France
| | - Clément Molina
- Institute for Research on Cancer and Aging (IRCAN), Université Côte d’Azur, CNRS UMR 7284 and INSERM U1081, 33 Avenue de Valombrose, 06107 Nice, France
| | - Patricia Piris
- Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli Calmettes, Aix-Marseille Université, Inserm U1068, CNRS UMR 758, 27 Boulevard Jean Moulin, 13273 Marseille, France
| | - Nouha Soufi
- Institute for Research on Cancer and Aging (IRCAN), Université Côte d’Azur, CNRS UMR 7284 and INSERM U1081, 33 Avenue de Valombrose, 06107 Nice, France
| | - Manon Carré
- Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli Calmettes, Aix-Marseille Université, Inserm U1068, CNRS UMR 758, 27 Boulevard Jean Moulin, 13273 Marseille, France
| | | | - Vincent Picco
- Centre Scientifique de Monaco (CSM), Biomedical Department, 98000 Monaco, Monaco
| | - Maeva Dufies
- Institute for Research on Cancer and Aging (IRCAN), Université Côte d’Azur, CNRS UMR 7284 and INSERM U1081, 33 Avenue de Valombrose, 06107 Nice, France
- Roca Therapeutics, 06000 Nice, France
| | - Cyril Ronco
- Roca Therapeutics, 06000 Nice, France
- Institut de Chimie de Nice UMR 7272, Université Côte d’Azur, Centre National de Recherche Scientifique (CNRS), 06108 Nice, France
| | - Rachid Benhida
- Roca Therapeutics, 06000 Nice, France
- Institut de Chimie de Nice UMR 7272, Université Côte d’Azur, Centre National de Recherche Scientifique (CNRS), 06108 Nice, France
| | - Sonia Martial
- Institute for Research on Cancer and Aging (IRCAN), Université Côte d’Azur, CNRS UMR 7284 and INSERM U1081, 33 Avenue de Valombrose, 06107 Nice, France
- Correspondence: ; Tel.: +33-4-92-03-12-29
| | - Gilles Pagès
- Institute for Research on Cancer and Aging (IRCAN), Université Côte d’Azur, CNRS UMR 7284 and INSERM U1081, 33 Avenue de Valombrose, 06107 Nice, France
- Centre Scientifique de Monaco (CSM), Biomedical Department, 98000 Monaco, Monaco
- Roca Therapeutics, 06000 Nice, France
| |
Collapse
|
2
|
Pagnuzzi-Boncompagni M, Picco V, Vial V, Planas-Bielsa V, Vandenberghe A, Daubon T, Derieppe MA, Montemagno C, Durivault J, Grépin R, Martial S, Doyen J, Gavard J, Pagès G. Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma. Cancers (Basel) 2021; 14:cancers14010070. [PMID: 35008234 PMCID: PMC8750527 DOI: 10.3390/cancers14010070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 12/14/2021] [Accepted: 12/15/2021] [Indexed: 01/06/2023] Open
Abstract
Simple Summary Medulloblastoma is the most frequent pediatric brain cancer. Despite great improvements in the treatment of this disease over the last decades, survivors are subject to debilitating adverse effects that strongly impair their quality of life. There is an urgent need to find efficient anticancer therapies with fewer toxic effects. In this study, we suggest that an FDA- and EMA-approved antiangiogenic compound named axitinib may display effective antitumoral effects and low toxicity towards children as compared to a reference treatment currently used in clinical protocols. We also show that this compound can enter the brain compartment and exert antitumoral effects in vivo. Our study paves the way towards a clinical trial of repurposing axitinib to a pediatric brain cancer indication. Abstract Background: Despite the improvement of medulloblastoma (MB) treatments, survivors face severe long-term adverse effects and associated morbidity following multimodal treatments. Moreover, relapses are fatal within a few months. Therefore, chemotherapies inducing fewer adverse effects and/or improving survival at relapse are key for MB patients. Our purpose was to evaluate the last-generation antiangiogenic drugs for their relevance in the therapeutic arsenal of MB. Methods: We screened three EMA- and FDA-approved antiangiogenic compounds (axitinib, cabozantinib and sunitinib) for their ability to reduce cell viability of five MB cell lines and their low toxicity towards two normal cell lines in vitro. Based on this screening, single-agent and combination therapies were designed for in vivo validation. Results: Axitinib, cabozantinib and sunitinib decreased viability of all the tested tumor cells. Although sunitinib was the most efficient in tumor cells, it also impacted normal cells. Therefore, axitinib showed the highest selectivity index for MB cells as compared to normal cells. The compound did not lead to acute toxicity in juvenile rats and crossed the blood–brain barrier. Moreover, axitinib efficiently reduced the growth rate of experimental brain tumors. Analysis of public databases showed that high expression of axitinib targets correlates with poor prognosis. Conclusion: Our results suggest that axitinib is a compelling candidate for MB treatment.
Collapse
Affiliation(s)
- Marina Pagnuzzi-Boncompagni
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
| | - Vincent Picco
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
- Correspondence: (V.P.); (G.P.); Tel.: +377-97-77-44-15 (V.P.); +33-4-92-03-12-39 (G.P.)
| | - Valérie Vial
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
| | | | - Ashaina Vandenberghe
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
| | - Thomas Daubon
- Institut de Biochimie et Génétique Cellulaires (IBGC), CNRS, University of Bordeaux, UMR 5095, 33000 Bordeaux, France;
| | - Marie-Alix Derieppe
- Animalerie Mutualisée, Service Commun des Animaleries, University of Bordeaux, 33600 Pessac, France;
| | - Christopher Montemagno
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
| | - Jérôme Durivault
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
| | - Renaud Grépin
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
| | - Sonia Martial
- Centre Antoine Lacassagne, Institute for Research on Cancer and Aging of Nice (IRCAN), University Nice Cote d’Azur, CNRS UMR 7284, INSERM U1081, 06189 Nice, France;
| | - Jérôme Doyen
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University of Côte d’Azur, Fédération Claude Lalanne, 06189 Nice, France;
| | - Julie Gavard
- Team SOAP, CRCINA, INSERM, CNRS, Université de Nantes, 44000 Nantes, France;
- Integrated Center of Oncology, 44800 St. Herblain, France
| | - Gilles Pagès
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (M.P.-B.); (V.V.); (A.V.); (C.M.); (J.D.); (R.G.)
- Centre Antoine Lacassagne, Institute for Research on Cancer and Aging of Nice (IRCAN), University Nice Cote d’Azur, CNRS UMR 7284, INSERM U1081, 06189 Nice, France;
- Correspondence: (V.P.); (G.P.); Tel.: +377-97-77-44-15 (V.P.); +33-4-92-03-12-39 (G.P.)
| |
Collapse
|
3
|
Dumond A, Brachet E, Durivault J, Vial V, Puszko AK, Lepelletier Y, Montemagno C, Pagnuzzi-Boncompagni M, Hermine O, Garbay C, Lagarde N, Montes M, Demange L, Grépin R, Pagès G. Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma. J Exp Clin Cancer Res 2021; 40:33. [PMID: 33461580 PMCID: PMC7812727 DOI: 10.1186/s13046-021-01832-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 01/07/2021] [Indexed: 12/13/2022]
Abstract
Background Despite the improvement of relapse-free survival mediated by anti-angiogenic drugs like sunitinib (Sutent®), or by combinations of anti-angiogenic drugs with immunotherapy, metastatic clear cell Renal Cell Carcinoma (mccRCC) remain incurable. Hence, new relevant treatments are urgently needed. The VEGFs coreceptors, Neuropilins 1, 2 (NRP1, 2) are expressed on several tumor cells including ccRCC. We analyzed the role of the VEGFs/NRPs signaling in ccRCC aggressiveness and evaluated the relevance to target this pathway. Methods We correlated the NRP1, 2 levels to patients’ survival using online available data base. Human and mouse ccRCC cells were knocked-out for the NRP1 and NRP2 genes by a CRISPR/Cas9 method. The number of metabolically active cells was evaluated by XTT assays. Migration ability was determined by wound closure experiments and invasion ability by using Boyden chamber coated with collagen. Production of VEGFA and VEGFC was evaluated by ELISA. Experimental ccRCC were generated in immuno-competent/deficient mice. The effects of a competitive inhibitor of NRP1, 2, NRPa-308, was tested in vitro and in vivo with the above-mentioned tests and on experimental ccRCC. NRPa-308 docking was performed on both NRPs. Results Knock-out of the NRP1 and NRP2 genes inhibited cell metabolism and migration and stimulated the expression of VEGFA or VEGFC, respectively. NRPa-308 presented a higher affinity for NRP2 than for NRP1. It decreased cell metabolism and migration/invasion more efficiently than sunitinib and the commercially available NRP inhibitor EG00229. NRPa-308 presented a robust inhibition of experimental ccRCC growth in immunocompetent and immunodeficient mice. Such inhibition was associated with decreased expression of several pro-tumoral factors. Analysis of the TCGA database showed that the NRP2 pathway, more than the NRP1 pathway correlates with tumor aggressiveness only in metastatic patients. Conclusions Our study strongly suggests that inhibiting NRPs is a relevant treatment for mccRCC patients in therapeutic impasses and NRPa-308 represents a relevant hit. Supplementary Information The online version contains supplementary material available at 10.1186/s13046-021-01832-x.
Collapse
Affiliation(s)
- Aurore Dumond
- Scientific Center of Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000, Monaco, Principality of Monaco.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco, Nice, France
| | - Etienne Brachet
- Université de Paris, CiTCoM, UMR 8038 CNRS, F-75006, Paris, France
| | - Jérôme Durivault
- Scientific Center of Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000, Monaco, Principality of Monaco.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco, Nice, France
| | - Valérie Vial
- Scientific Center of Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000, Monaco, Principality of Monaco.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco, Nice, France
| | - Anna K Puszko
- Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093, Warsaw, Poland
| | - Yves Lepelletier
- INSERM UMR 1163, Laboratory of Cellular and Molecular Basis of Normal Hematopoiesis and Hematological Disorders: Therapeutical Implications, F-75015, Paris, France.,Université de Paris, Imagine Institut, F-75015, Paris, France
| | - Christopher Montemagno
- Scientific Center of Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000, Monaco, Principality of Monaco.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco, Nice, France
| | - Marina Pagnuzzi-Boncompagni
- Scientific Center of Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000, Monaco, Principality of Monaco.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco, Nice, France
| | - Olivier Hermine
- INSERM UMR 1163, Laboratory of Cellular and Molecular Basis of Normal Hematopoiesis and Hematological Disorders: Therapeutical Implications, F-75015, Paris, France.,Université de Paris, Imagine Institut, F-75015, Paris, France
| | - Christiane Garbay
- Université de Paris, LCBPT, UMR8601 CNRS, UFR Biomédicale des Saints-Pères, F-75006, Paris, France
| | - Nathalie Lagarde
- Laboratoire GBCM EA7528, Conservatoire National des Arts et Métiers, HESAM Université, 2 Rue Conté, 75003, Paris, France
| | - Matthieu Montes
- Laboratoire GBCM EA7528, Conservatoire National des Arts et Métiers, HESAM Université, 2 Rue Conté, 75003, Paris, France
| | - Luc Demange
- Université de Paris, CiTCoM, UMR 8038 CNRS, F-75006, Paris, France.,Université Côte d'Azur, ICN, UMR 7272 CNRS, F-06108, Nice, France
| | - Renaud Grépin
- Scientific Center of Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000, Monaco, Principality of Monaco.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco, Nice, France
| | - Gilles Pagès
- Scientific Center of Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000, Monaco, Principality of Monaco. .,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco, Nice, France. .,University Cote d'Azur (UCA), Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, Nice, France.
| |
Collapse
|
4
|
Cormerais Y, Pagnuzzi-Boncompagni M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe MF, Pagès G, Pouysségur J, Picco V. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. J Cell Mol Med 2019; 23:2711-2718. [PMID: 30784173 PMCID: PMC6433660 DOI: 10.1111/jcmm.14176] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 12/29/2018] [Accepted: 01/02/2019] [Indexed: 12/19/2022] Open
Abstract
Most cases of medulloblastoma (MB) occur in young children. While the overall survival rate can be relatively high, current treatments combining surgery, chemo‐ and radiotherapy are very destructive for patient development and quality of life. Moreover, aggressive forms and recurrences of MB cannot be controlled by classical therapies. Therefore, new therapeutic approaches yielding good efficacy and low toxicity for healthy tissues are required to improve patient outcome. Cancer cells sustain their proliferation by optimizing their nutrient uptake capacities. The L‐type amino acid transporter 1 (LAT1) is an essential amino acid carrier overexpressed in aggressive human cancers that was described as a potential therapeutic target. In this study, we investigated the therapeutic potential of JPH203, a LAT1‐specific pharmacological inhibitor, on two independent MB cell lines belonging to subgroups 3 (HD‐MB03) and Shh (DAOY). We show that while displaying low toxicity towards normal cerebral cells, JPH203 disrupts AA homeostasis, mTORC1 activity, proliferation and survival in MB cells. Moreover, we demonstrate that a long‐term treatment with JPH203 does not lead to resistance in MB cells. Therefore, this study suggests that targeting LAT1 with JPH203 is a promising therapeutic approach for MB treatment.
Collapse
Affiliation(s)
- Yann Cormerais
- Biomedical Department, Centre Scientifique de Monaco, Monaco, Principality of Monaco
| | | | - Sandra Schrötter
- Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| | - Sandy Giuliano
- Biomedical Department, Centre Scientifique de Monaco, Monaco, Principality of Monaco
| | - Eric Tambutté
- Marine Biology Department, Centre Scientifique de Monaco, Monaco, Principality of Monaco
| | | | - Michael F Wempe
- School of Pharmacy, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado
| | - Gilles Pagès
- Biomedical Department, Centre Scientifique de Monaco, Monaco, Principality of Monaco.,Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, University of Cote d'Azur, Nice, France
| | - Jacques Pouysségur
- Biomedical Department, Centre Scientifique de Monaco, Monaco, Principality of Monaco.,Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, University of Cote d'Azur, Nice, France
| | - Vincent Picco
- Biomedical Department, Centre Scientifique de Monaco, Monaco, Principality of Monaco
| |
Collapse
|